S10 Ep19: FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer

from OncLive® On Air · host OncLive® On Air

Dr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma, key data from NAPOLI 3, and the potential evolution of NALIRIFOX’s role in the treatment of patients with pancreatic cancer.

Episode metadata supplied by the publisher feed · Published Mar 11, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

S10 Ep19: FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer

0:00 7:19

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 7 minutes long.

When was this OncLive® On Air episode published?

This episode was published on March 11, 2024.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!